


PHARMACEUTICAL 2018

ANAPTYSBIO INC Rank 34 of 349







PHARMACEUTICAL 2018



ANAPTYSBIO INC Rank 34 of 349



The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of ANAPTYSBIO INC is the variable Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 408% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	252,696
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,090
Liabilities, Non-Current	0
Other Assets	76,003
Other Compr. Net Income	-426
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,289
Property and Equipment	665
Research and Development	29,443
Revenues	10,000
Selling, General and Administrative Expense	9,338

Output Variable	Value in 1000 USD
Assets	329,364
Liabilities	14,090
Expenses	38,781
Stockholders Equity	315,274
Net Income	-30,070
Comprehensive Net Income	-30,283
Economic Capital Ratio	130%